Orozco CA, Liu WYC

Language: Spanish
References: 16
Page: 173-177
PDF size: 236.45 Kb.

ABSTRACT

Treatment of diabetic patients with diabetic foot infection is highly complex because of the multiple factors involved in its development. A rapid diagnosis and early initiation of empirical antibiotic therapy directed at the organisms causing the infection (see Table 1) are vital in order to keep the affected limb, thus was born the idea of presenting a set of guidelines based on the best evidence found aimed to obtain the greatest clinical efficacy by reviewing international literature some empirical antibiotic therapy of diabetic foot infections.

REFERENCES

1. Centers for Disease Control and Prevention. Vancomycinresistant Staphylococcus aureus- Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002; 51: 902.

2. Dang C, Prasad Y, Bouton A, Jude EB. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 2003; 20: 15119. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002; 49: 999-1005.

3. Ellis-Grosse EJ, Babinchak T, Loh E for the Tigecycline cSSSI Study Groups. The efficacy and safety of tigecycline in the treatment of skin and skinstructure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41: S341-53.

4. Grayson ML, Gibbons GW, et al. Use of ampicillin/ sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1994; 18: 683-93.

5. Herranz A, Barberán J, Gomis M, Alguacil R, Pastor JM. Cefotaxima en el tratamiento de las osteomielitis en el pie del diabético. An Med Med (Madrid) 1991; 8: 273-80.

6. J.A. García-Rodríguez. Documento de consenso sobre el tratamiento antimicrobiano de las infecciones en el pie diabético. Rev Med Española 2008; 60:83-101.

7. Karchmer AW, Gibbons GW. Foot infections in diabetes: evaluation and management. In Remington JS, Swartz MN, eds. Current clinical topics in infectious diseases. Cambridge: Blackwell Scientific; 1994. p. 1-22.

8. Laethem T, De Lepeleire I, McCrea J, Zhang J, Majumdar A, Musson D, et al. Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suctioninduced skin blister fluid in healthy young volunteers. Antimicrob Agents Chemother 2003; 47: 1439- 42.

9. Levin ME. Management of the diabetic foot: preventing amputation. South Med J 2002; 95: 10-20.

10. Lipsky BA, Berendt AR, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004; 39: 885-910.

11. Lipsky BA. Medical treatment of diabetic foot infections. Clin Infect Dis 2004; 39: S104-14.

12. Lipsky BA, Armstrong DG. Ertapenem versus piperacillin/ tazobactam for diabetic foot infections: prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 2005; 366: 1695-703.

13. Lipsky BA, Itani K, Norden C, Linezolid Diabetic Foot Infections Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillinsulbactam/ amoxicillin-clavulanate. Clin Infect Dis 2004; 38: 17-24.

14. Raymakers JT, Houben AJ. The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissues of the limb. Diabet Med 2001; 18: 229-34.

15. Tentolouris N, Jude EB, Smirnof I, Knowles EA, Boulton AJ. Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med 1999; 16: 767-71.

16. Zeillemaker AM,Veldkamp KE,Van Kraaij MG, Hoekstra JB, Hoynck AA, Diepersloot RJ. Piperacillin/ tazobactam therapy for diabetic foot infection. Foot Ankle Int 1998; 19: 169-72. 9-61.